You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Unicondylar Resurfacing in an Ovine Osteoarthritis Disease Model

    SBC: Cytex Therapeutics, Inc.            Topic: NIAMS

    AbstractThe treatment of large cartilage lesions is a difficult clinical problem for which there are few good solutionsLeft untreatedthese lesions tend to degenerate to chronic pain and osteoarthritisOAultimately requiring a total joint replacementFor patients suffering from knee OAandin particularunicompartmental OAunicondylar knee arthroplastyUKAis an available first line treatment option that p ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  2. Development of user-friendly fluorescence based assays for marine toxins

    SBC: SeaTox Research Inc            Topic: 113

    ABSTRACTHarmful algal bloomsHABsare becoming frequent occurrences off the coasts of the United Stateswith specific instances in the coastal waters of the west coastthe Gulf of Mexicoand the Pacific OceanHistoricallyHABs have been associated with fish kills and marine mammal mortalitieshowevertheir effects on human health and economic loss due to HAB contamination of seafood are becoming more preva ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  3. Microfluidic Nitric Oxide Sensor

    SBC: CLINICAL SENSORS, INC.            Topic: NIAID

    PROJECT SUMMARY Clinical Sensors has developed a manufacturable prototype microfluidic sensor for measuring nitric oxide in whole bloodThis STTR Phase II project aims to complete several key aims necessary to commercialize this deviceincluding a clinical study where NO levels will be evaluated clinically in sepsisSepsis is the leading cause of death in non cardiac intensive care unitsICUsEach year ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  4. Novel Small Molecule Macrophage Inhibitors for the Treatment of Retinal Diseases

    SBC: Eyedesis Biosciences, LLC            Topic: N

    PROJECT SUMMARY ABSTRACT Persistent disease activity PDA in spite of anti vascular endothelial growth factor VEGF therapy remains a significant clinical unmet need for patients with neovascular age related macular degeneration NVAMD The purpose of this STTR Phase I grant application is to develop novel therapies that will be effective for the treatment of PDA associated with NVAMD The cu ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  5. Towards a New Generation of Glycoengineered Pneumococcal Bioconjugate Vaccines

    SBC: VaxNewMO            Topic: NIAID

    PROJECT SUMMARY Pneumococcal pneumonia remains the leading cause of bacterial pneumonia in both children under years of age and adults over years of age The standard preventative therapy is the conjugate vaccine Prevnar which consists of an immunogenic carrier protein covalently attached to one of thirteen pneumococcal capsular polysaccharides Although Prevnar has significantly red ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  6. Personalized Neural Stem Cell Therapy for Cancer

    SBC: Falcon Therapeutics, Inc.            Topic: NCATS

    Project Summary Abstract Glioblastoma GBM is the most common primary brain tumor and one of the deadliest forms of cancer Standard surgery chemotherapy and radiation fail to eliminate the infiltrative invasive cancer cells Median survival remains only months Drugs that seek out the disseminated GBM cells behind the blood brain barrier will prevent the inevitable recurrence in patients ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  7. High throughput CRISPR Cas cell line generation using the CellRaft Array platform

    SBC: Cell Microsystems, Inc.            Topic: NHGRI

    Project Summary Genome editing technologies such CRISPR Cas provide a rapid and targeted means of both knocking out gene expression and knocking in gene modifications However the current workflow required for CRISPR cell line generation relies on several technologies which reduce throughput efficiency and the overall viability of genome edited cells Cell Microsystems has developed a single ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  8. Artificial neural networks for high performance fully automated particle tracking analysis even at low signal to noise regimes

    SBC: AI Tracking Solutions LLC            Topic: 400

    Abstract Particle tracking PT is a powerful biophysical tool for elucidating molecular interactions transport phenomena and rheological properties in complex biological environments Unfortunately PT remains a niche tool in life and physical sciences with a limited user base in large part due to significant time and technical constraints in extracting accurate time variant positional data fr ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  9. Developing a new therapeutic agent for retinal ciliopathies

    SBC: Rescindo Therapeutics Inc            Topic: N

    The ciliopathies are a group of andgt overlapping clinical disorders caused by defects in the primary cilium and its anchoring structure the basal body Although individually rare this group contributes significantly to the population genetic disease burden with some estimates placing their combined incidence to as much as Importantly although some ciliopathies are lethal most pat ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  10. ErythroMer Nanoscale Bio Synthetic Red Cell Substitute

    SBC: KaloCyte Inc            Topic: NHLBI

    PROJECT SUMMARY There is need for an artificial oxygen O carrier to substitute for banked blood in settings where stored blood is unavailable pre hospital care transport austere environments undeveloped countries or undesirable transfusion risk exceeds benefit To address this need we developed ErythroMer EM a first in class nano cyte blood substitute EM is a deformable ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government